Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride
Identifieur interne : 001697 ( Istex/Curation ); précédent : 001696; suivant : 001698Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride
Auteurs : Angelo Antonini [Suisse] ; Johannes Schwarz [Suisse] ; Wolfgang H. Oertel [Suisse] ; Oliver Pogarell [Suisse] ; Leenders [Suisse, Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 1997-01.
English descriptors
Abstract
We used [11C]raclopride (RACLO) and positron emission tomography (PET) to study longitudinally striatal dopamine D2 receptor binding in nine patients with Parkinson's disease (PD) at an early drug‐naive stage and 3–5 years later, when motor fluctuations had appeared in seven of them. Patients were treated with a combination of levodopa and dopamine agonists. Data were compared with 10 healthy controls in the same age range. Initially, patients with PD showed a significant increase of RACLO uptake in the putamen compared with controls (p < 0.04). The caudate nucleus revealed values in the normal range. After 3–5 years, RACLO binding was significantly reduced in the putamen (p < 0.03) and caudate nucleus (p < 0.03) compared with baseline. Values were now in the control range in the putamen and reduced in the caudate nucleus (p < 0.05). The clinical score at “off” had significantly worsened (p < 0.0005) compared with the first PET scan. The nine PD patients reported here had already been investigated 3–4 months after therapy began and at that time did not show a reduction of the initially increased RACLO binding capacity (data published previously). These results indicate long‐term downregulation of striatal dopamine D2 receptor binding in PD. Receptor changes in the striatum of patients with PD may be induced by chronic dopaminergic therapy or occur independently of treatment, as a result of structural adaptation of the postsynaptic dopaminergic system to the progressive decline of nigrostriatal neurons.
Url:
DOI: 10.1002/mds.870120107
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001697
Links to Exploration step
ISTEX:B6E9D4BE9B82257D2DDDF0C976C381F6BA037634Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride</title><author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name><affiliation wicri:level="1"><mods:affiliation>PET Department, Paul Scherrer Institute, Villigen, University Hospital Zurich, Zurich, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>PET Department, Paul Scherrer Institute, Villigen, University Hospital Zurich, Zurich</wicri:regionArea></affiliation></author><author><name sortKey="Schwarz, Johannes" sort="Schwarz, Johannes" uniqKey="Schwarz J" first="Johannes" last="Schwarz">Johannes Schwarz</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital Zurich, Zurich, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Neurology, University Hospital Zurich, Zurich</wicri:regionArea></affiliation></author><author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital Zurich, Zurich, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Neurology, University Hospital Zurich, Zurich</wicri:regionArea></affiliation></author><author><name sortKey="Pogarell, Oliver" sort="Pogarell, Oliver" uniqKey="Pogarell O" first="Oliver" last="Pogarell">Oliver Pogarell</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital Zurich, Zurich, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Neurology, University Hospital Zurich, Zurich</wicri:regionArea></affiliation></author><author><name sortKey="Leenders" sort="Leenders" uniqKey="Leenders" last="Leenders">Leenders</name><affiliation wicri:level="1"><mods:affiliation>PET Department, Paul Scherrer Institute, Villigen, University Hospital Zurich, Zurich, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>PET Department, Paul Scherrer Institute, Villigen, University Hospital Zurich, Zurich</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Klinikum Grosshadern, Ludwig‐Maximilians University, Munich, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwig‐Maximilians University, Munich</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B6E9D4BE9B82257D2DDDF0C976C381F6BA037634</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1002/mds.870120107</idno><idno type="url">https://api.istex.fr/document/B6E9D4BE9B82257D2DDDF0C976C381F6BA037634/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001697</idno><idno type="wicri:Area/Istex/Curation">001697</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride</title><author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name><affiliation wicri:level="1"><mods:affiliation>PET Department, Paul Scherrer Institute, Villigen, University Hospital Zurich, Zurich, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>PET Department, Paul Scherrer Institute, Villigen, University Hospital Zurich, Zurich</wicri:regionArea></affiliation></author><author><name sortKey="Schwarz, Johannes" sort="Schwarz, Johannes" uniqKey="Schwarz J" first="Johannes" last="Schwarz">Johannes Schwarz</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital Zurich, Zurich, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Neurology, University Hospital Zurich, Zurich</wicri:regionArea></affiliation></author><author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital Zurich, Zurich, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Neurology, University Hospital Zurich, Zurich</wicri:regionArea></affiliation></author><author><name sortKey="Pogarell, Oliver" sort="Pogarell, Oliver" uniqKey="Pogarell O" first="Oliver" last="Pogarell">Oliver Pogarell</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University Hospital Zurich, Zurich, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Neurology, University Hospital Zurich, Zurich</wicri:regionArea></affiliation></author><author><name sortKey="Leenders" sort="Leenders" uniqKey="Leenders" last="Leenders">Leenders</name><affiliation wicri:level="1"><mods:affiliation>PET Department, Paul Scherrer Institute, Villigen, University Hospital Zurich, Zurich, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>PET Department, Paul Scherrer Institute, Villigen, University Hospital Zurich, Zurich</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Klinikum Grosshadern, Ludwig‐Maximilians University, Munich, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwig‐Maximilians University, Munich</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1997-01">1997-01</date><biblScope unit="vol">12</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="33">33</biblScope><biblScope unit="page" to="38">38</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">B6E9D4BE9B82257D2DDDF0C976C381F6BA037634</idno><idno type="DOI">10.1002/mds.870120107</idno><idno type="ArticleID">MDS870120107</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine D2 receptors</term><term>Parkinson's disease</term><term>Positron emission tomography</term><term>[11C]Raclopride</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We used [11C]raclopride (RACLO) and positron emission tomography (PET) to study longitudinally striatal dopamine D2 receptor binding in nine patients with Parkinson's disease (PD) at an early drug‐naive stage and 3–5 years later, when motor fluctuations had appeared in seven of them. Patients were treated with a combination of levodopa and dopamine agonists. Data were compared with 10 healthy controls in the same age range. Initially, patients with PD showed a significant increase of RACLO uptake in the putamen compared with controls (p < 0.04). The caudate nucleus revealed values in the normal range. After 3–5 years, RACLO binding was significantly reduced in the putamen (p < 0.03) and caudate nucleus (p < 0.03) compared with baseline. Values were now in the control range in the putamen and reduced in the caudate nucleus (p < 0.05). The clinical score at “off” had significantly worsened (p < 0.0005) compared with the first PET scan. The nine PD patients reported here had already been investigated 3–4 months after therapy began and at that time did not show a reduction of the initially increased RACLO binding capacity (data published previously). These results indicate long‐term downregulation of striatal dopamine D2 receptor binding in PD. Receptor changes in the striatum of patients with PD may be induced by chronic dopaminergic therapy or occur independently of treatment, as a result of structural adaptation of the postsynaptic dopaminergic system to the progressive decline of nigrostriatal neurons.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001697 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001697 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:B6E9D4BE9B82257D2DDDF0C976C381F6BA037634
|texte= Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride
}}
| This area was generated with Dilib version V0.6.23. |  |